Akira Inoue

Akira Inoue

Auto-generated profile, based on publicly available information

Akira Inoue

Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
EMEisaku Miyauchi
Eisaku Miyauchi
SMSatoshi Morita
Satoshi Morita
ANAtsushi Nakamura
Atsushi Nakamura
YHYukio Hosomi
Yukio Hosomi
KWKana Watanabe
Kana Watanabe
FGfor the North-East Japan Study Group
for the North-East Japan Study Group
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with gefitinib-alone in patients with untreated non–small-cell lung cancer harboring mutations in epidermal growth factor receptor. Herein, we report the updated survival outcome and long-term tolerability. Patients were randomly assigned to gefitinib (gefitinib 250 mg orally, once daily) and gefitinib combined with carboplatin plus pemetrexed (GCP in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance) groups. At the data cutoff (May 22, 2020), GCP demonstrated significantly better PFS2 (hazard ratio, 0.77; 95% CI, 0.62 to 0.97; P = .027) than gefitinib. However, the updated median OS was 38.5 months (95% CI, 31.1 to 47.1) and 49.0 months (95% CI, 41.8 to 56.7) in the gefitinib and GCP groups, respectively (hazard ratio, 0.82; 95% CI, 0.64 to 1.06; P = .127). The OS in both groups was similar for the overall patient population. No severe adverse events occurred since the first report. This updated analysis revealed that the GCP regimen improved PFS and PFS2 with an acceptable safety profile compared with gefitinib-alone. GCP is more efficient than gefitinib monotherapy as a first-line treatment for non–small-cell lung cancer with epidermal growth factor receptor mutations.

11 February 2019 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
YTYoko Tsukita
Yoko Tsukita
NFNaoya Fujino
Naoya Fujino
EMEisaku Miyauchi
Eisaku Miyauchi
RSRyoko Saito-Koyama
Ryoko Saito-Koyama
FFFumiyoshi Fujishima
Fumiyoshi Fujishima
MIMasakazu Ichinose
Masakazu Ichinose
Axl receptor tyrosine kinase is involved in the growth and metastasis and is an indicator of poor prognosis in several cancers including lung cancers. Although a mitogen-activated protein kinase (MAPK) pathway and an epithelial-to-mesenchymal transition (EMT) program are critical, molecular mechanisms underlying the Axl-driven cancer progression have not been fully elucidated. We aimed to identify molecules up-regulated by Axl kinase in lung adenocarcinomas. Through the global gene expression analysis and the functional annotation clustering, we found that AXL expression positively correlated with mRNA expressions of immune checkpoint molecules and chemokine receptors in non-small-cell lung cancers. Validation cohorts including our biobank confirmed that the AXL expression significantly correlated with expression of genes encoding programmed death-ligand1 (PD-L1) and CXC chemokine receptor 6 (CXCR6) in lung adenocarcinoma, especially in epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma. Pharmacological inhibition of Axl kinase activity decreased mRNA expressions of PD-L1 and CXCR6 in EGFR mutation-positive cell lines. Our data indicates the novel role of Axl kinase as a driver of immune checkpoint molecules and chemokine signalling pathways in the progression of lung adenocarcinomas. This study also highlights the necessity of clinical trials in order to test the efficacy of Axl kinase inhibition in the Axl-highly expressing subset of lung adenocarcinomas.

1 March 2018 in Lung Cancer
Verified
Journal Article
Open access
IOIsamu Okamoto
Isamu Okamoto
SMSatoshi Morita
Satoshi Morita
NTNaoki Tashiro
Naoki Tashiro
FIFumio Imamura
Fumio Imamura
AIAkira Inoue
Akira Inoue
MFMasahiro Fukuoka
Masahiro Fukuoka
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.

1 January 2020 in Lung Cancer
Verified
Journal Article
Closed access
YTYoko Tsukita
Yoko Tsukita
AIAkira Inoue
Akira Inoue
SSShunichi Sugawara
Shunichi Sugawara
SKShoichi Kuyama
Shoichi Kuyama
TNTaku Nakagawa
Taku Nakagawa
MIMasakazu Ichinose
Masakazu Ichinose

21 December 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
TITomoo Ikari
Tomoo Ikari
YHYusuke Hiratsuka
Yusuke Hiratsuka
TYTakuhiro Yamaguchi
Takuhiro Yamaguchi
IMIsseki Maeda
Isseki Maeda
MMMasanori Mori
Masanori Mori
AIAkira Inoue
Akira Inoue
Background: The study aimed to clarify the efficacy of the “3‐Day Surprise Question (3DSQ)” in predicting the prognosis for advanced cancer patients with impending death.Patients and Methods: This study was a part of multicenter prospective observational study which investigated the dying process in advanced cancer patients in Japan. For patients with a Palliative Performance Scale ≤20, the 3DSQ “Would I be surprised if this patient died in the next 3 days?” was answered by their physicians. In addition to the sensitivity and specificity of the 3DSQ, the characteristics of patients who survived longer than expected were examined via multivariate analysis.Results: Among the 1896 patients enrolled, 1411 were evaluated. Among 1179 (83.6%) patients who were classified into the “Not surprised” group, 636 patients died within 3 days. Among 232 (16.4%) patients of “Yes surprised” group, 194 patients lived longer than 3 days. The sensitivity, specificity, positive predictive value, and negative predictive value of the 3DSQ were 94.3% (95% confidence interval [CI]: 92.7% to 95.8%), 26.3% (95% CI: 24.8% to 27.6%), 53.9% (95% CI: 53.0% to 54.7%), and 83.6% (95% CI: 78.7% to 87.7%), respectively. Multivariate analysis showed palpable radial artery, absent respiration with mandibular movement, SpO2 ≥ 90%, opioid administration, and no continuous deep sedation as characteristics of patients who lived longer than expected.Conclusions: The 3‐Day Surprise Question can be a useful screening tool to identify advanced cancer patients with impending death.

17 April 2020 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
YHYusuke Hiratsuka
Yusuke Hiratsuka
TYTakuhiro Yamaguchi
Takuhiro Yamaguchi
IMIsseki Maeda
Isseki Maeda
TMTatsuya Morita
Tatsuya Morita
MMMasanori Mori
Masanori Mori
AIAkira Inoue
Akira Inoue